Skip to main content

Bladder Preservation Therapies in Bladder Cancer

  • 1028 Accesses

Abstract

Intravesical therapies with close monitoring are adequate for superficial disease, and chemotherapy and palliative radiotherapy are the main treatment options in metastatic stages. For muscle-invasive disease, treatment strategies are basically divided into two groups: surgery vs. trimodality treatment (TMT) that involves transurethral resection (TUR) of tumor tissues and concurrent radiochemotherapy (RCT); radiotherapy (RT) monotherapy is not recommended as primary curative option, and multimodality treatment is currently regarded only as an alternative in selected, well-informed, and compliant patients in whom cystectomy is not considered for clinical or personal reasons.

Keywords

  • Bladder cancer
  • Radiotherapy
  • Bladder preservation

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-319-56114-1_4
  • Chapter length: 17 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   139.00
Price excludes VAT (USA)
  • ISBN: 978-3-319-56114-1
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   179.99
Price excludes VAT (USA)
Hardcover Book
USD   179.99
Price excludes VAT (USA)
Fig. 4.1
Fig. 4.2
Fig. 4.3
Fig. 4.4
Fig. 4.5

References

  1. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends – an update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16–27. doi:10.1158/1055-9965.EPI-15-0578.

  2. Zaghloul MS, Mousa AG. Trimodality treatment for bladder cancer: does modern radiotherapy improve the end results? Expert Rev Anticancer Ther. 2010;10(12):1933–44. doi:10.1586/era.10.156.

    CrossRef  Google Scholar 

  3. Secin FP, Karanikolas N, Gopalan A, Bianco FJ, Shayegan B, Touijer K, et al. The anterior layer of Denonvilliers’ fascia: a common misconception in the laparoscopic prostatectomy literature. J Urol. 2007;177(2):521–5. doi:10.1016/j.juro.2006.09.028.

    CrossRef  PubMed  Google Scholar 

  4. Stenzl A, Cowan NC, De Santis M, Jakse G, Kuczyk MA, Merseburger AS, et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2009;55(4):815–25. doi:10.1016/j.eururo.2009.01.002.

    CrossRef  PubMed  Google Scholar 

  5. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Actas Urol Esp. 2012;36(7):389–402. doi:10.1016/j.acuro.2011.12.001.

    CAS  CrossRef  PubMed  Google Scholar 

  6. Burger M, Oosterlinck W, Konety B, Chang S, Gudjonsson S, Pruthi R, et al. ICUD-EAU international consultation on bladder cancer 2012: non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013;63(1):36–44. doi:10.1016/j.eururo.2012.08.061.

    CrossRef  PubMed  Google Scholar 

  7. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2008;54(2):303–14. doi:10.1016/j.eururo.2008.04.051.

    CrossRef  PubMed  Google Scholar 

  8. Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007;178(6):2314–30. doi:10.1016/j.juro.2007.09.003.

    CrossRef  PubMed  Google Scholar 

  9. Shelley MD, Jones G, Cleves A, Wilt TJ, Mason MD, Kynaston HG. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review. BJU Int. 2012;109(4):496–505. doi:10.1111/j.1464-410X.2011.10880.x.

    CAS  CrossRef  PubMed  Google Scholar 

  10. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666–75. doi:10.1200/jco.2001.19.3.666.

    CAS  CrossRef  PubMed  Google Scholar 

  11. Duncan W, Quilty PM. The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy. Radiother Oncol. 1986;7(4):299–310.

    CAS  CrossRef  PubMed  Google Scholar 

  12. Gospodarowicz MK, Rider WD, Keen CW, Connolly JG, Jewett MA, Cummings BJ, et al. Bladder cancer: long-term follow-up results of patients treated with radical radiation. Clin Oncol (R Coll Radiol). 1991;3(3):155–61.

    CAS  CrossRef  Google Scholar 

  13. Weiss C, Wolze C, Engehausen DG, Ott OJ, Krause FS, Schrott KM, et al. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy? J Clin Oncol. 2006;24(15):2318–24. doi:10.1200/JCO.2006.05.8149.

    CrossRef  PubMed  Google Scholar 

  14. Harland SJ, Kynaston H, Grigor K, Wallace DM, Beacock C, Kockelbergh R, et al. A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder. J Urol. 2007;178(3 Pt 1):807–13; discussion 13. doi:10.1016/j.juro.2007.05.024.

    CAS  CrossRef  PubMed  Google Scholar 

  15. Gakis G, Efstathiou J, Lerner SP, Cookson MS, Keegan KA, Guru KA, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013;63(1):45–57. doi:10.1016/j.eururo.2012.08.009.

    CrossRef  PubMed  Google Scholar 

  16. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–66. doi:10.1056/NEJMoa022148.

    CAS  CrossRef  PubMed  Google Scholar 

  17. Chahal R, Sundaram SK, Iddenden R, Forman DF, Weston PM, Harrison SC. A study of the morbidity, mortality and long-term survival following radical cystectomy and radical radiotherapy in the treatment of invasive bladder cancer in Yorkshire. Eur Urol. 2003;43(3):246–57.

    CAS  CrossRef  PubMed  Google Scholar 

  18. Kotwal S, Choudhury A, Johnston C, Paul AB, Whelan P, Kiltie AE. Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center. Int J Radiat Oncol Biol Phys. 2008;70(2):456–63. doi:10.1016/j.ijrobp.2007.06.030.

    CrossRef  PubMed  Google Scholar 

  19. Munro NP, Sundaram SK, Weston PM, Fairley L, Harrison SC, Forman D, et al. A 10-year retrospective review of a nonrandomized cohort of 458 patients undergoing radical radiotherapy or cystectomy in Yorkshire, UK. Int J Radiat Oncol Biol Phys. 2010;77(1):119–24. doi:10.1016/j.ijrobp.2009.04.050.

    CrossRef  PubMed  Google Scholar 

  20. Rene NJ, Cury FB, Souhami L. Conservative treatment of invasive bladder cancer. Curr Oncol. 2009;16(4):36–47.

    CAS  PubMed Central  Google Scholar 

  21. Langsenlehner T, Doller C, Quehenberger F, Stranzl-Lawatsch H, Langsenlehner U, Pummer K, et al. Treatment results of radiation therapy for muscle-invasive bladder cancer. Strahlenther Onkol. 2010;186(4):203–9. doi:10.1007/s00066-010-2053-1.

    CrossRef  PubMed  Google Scholar 

  22. Hall RR, Newling DW, Ramsden PD, Richards B, Robinson MR, Smith PH. Treatment of invasive bladder cancer by local resection and high dose methotrexate. Br J Urol. 1984;56(6):668–72.

    CAS  CrossRef  Google Scholar 

  23. Herr HW, Bajorin DF, Scher HI. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol. 1998;16(4):1298–301. doi:10.1200/jco.1998.16.4.1298.

    CAS  CrossRef  PubMed  Google Scholar 

  24. Prout GR Jr, Shipley WU, Kaufman DS, Heney NM, Griffin PP, Althausen AF, et al. Preliminary results in invasive bladder cancer with transurethral resection, neoadjuvant chemotherapy and combined pelvic irradiation plus cisplatin chemotherapy. J Urol. 1990;144(5):1128–34. discussion 34–6

    CrossRef  PubMed  Google Scholar 

  25. Coppin CM, Gospodarowicz MK, James K, Tannock IF, Zee B, Carson J, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1996;14(11):2901–7. doi:10.1200/jco.1996.14.11.2901.

    CAS  CrossRef  PubMed  Google Scholar 

  26. Chung PW, Bristow RG, Milosevic MF, Yi QL, Jewett MA, Warde PR, et al. Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urol Oncol. 2007;25(4):303–9. doi:10.1016/j.urolonc.2006.09.015.

    CrossRef  Google Scholar 

  27. Shipley WU, Winter KA, Kaufman DS, Lee WR, Heney NM, Tester WR, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol. 1998;16(11):3576–83. doi:10.1200/jco.1998.16.11.3576.

    CAS  CrossRef  Google Scholar 

  28. Rodel C, Weiss C, Sauer R. Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol. 2006;24(35):5536–44. doi:10.1200/JCO.2006.07.6729.

    CrossRef  PubMed  Google Scholar 

  29. Sangar VK, McBain CA, Lyons J, Ramani VA, Logue JP, Wylie JP, et al. Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer. Int J Radiat Oncol Biol Phys. 2005;61(2):420–5. doi:10.1016/j.ijrobp.2004.05.074.

  30. Housset M, Maulard C, Chretien Y, Dufour B, Delanian S, Huart J, et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol. 1993;11(11):2150–7. doi:10.1200/jco.1993.11.11.2150.

    CAS  CrossRef  PubMed  Google Scholar 

  31. James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366(16):1477–88. doi:10.1056/NEJMoa1106106.

    CAS  CrossRef  PubMed  Google Scholar 

  32. Tunio MA, Hashmi A, Qayyum A, Mohsin R, Zaeem A. Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience. Int J Radiat Oncol Biol Phys. 2012;82(3):e457–62. doi:10.1016/j.ijrobp.2011.05.051.

    CrossRef  PubMed  Google Scholar 

  33. Hussain SA, Stocken DD, Peake DR, Glaholm JG, Zarkar A, Wallace DM, et al. Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. Br J Cancer. 2004;90(11):2106–11. doi:10.1038/sj.bjc.6601852.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Peyromaure M, Slama J, Beuzeboc P, Ponvert D, Debre B, Zerbib M. Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: report of a single institution. Urology. 2004;63(1):73–7.

    CrossRef  Google Scholar 

  35. Kragelj B, Zaletel-Kragelj L, Sedmak B, Cufer T, Cervek J. Phase II study of radiochemotherapy with vinblastine in invasive bladder cancer. Radiother Oncol. 2005;75(1):44–7. doi:10.1016/j.radonc.2005.01.007.

    CAS  CrossRef  PubMed  Google Scholar 

  36. Aboziada MA, Hamza HM, Abdlrahem AM. Initial results of bladder preserving approach by chemo-radiotherapy in patients with muscle invading transitional cell carcinoma. J Egypt Natl Canc Inst. 2009;21(2):167–74.

    PubMed  Google Scholar 

  37. Choudhury A, Cowan R. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer. BJU Int. 2011;108(9):E313. doi:10.1111/j.1464-410X.2011.10672_3.x.

    CrossRef  PubMed  Google Scholar 

  38. Choudhury A, Swindell R, Logue JP, Elliott PA, Livsey JE, Wise M, et al. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. J Clin Oncol. 2011;29(6):733–8. doi:10.1200/JCO.2010.31.5721.

    CrossRef  PubMed  Google Scholar 

  39. Efstathiou JA, Spiegel DY, Shipley WU, Heney NM, Kaufman DS, Niemierko A, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol. 2012;61(4):705–11. doi:10.1016/j.eururo.2011.11.010.

    CrossRef  PubMed  Google Scholar 

  40. Rodel C, Grabenbauer GG, Kuhn R, Papadopoulos T, Dunst J, Meyer M, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002;20(14):3061–71.

    CrossRef  Google Scholar 

  41. Tester W, Porter A, Asbell S, Coughlin C, Heaney J, Krall J, et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys. 1993;25(5):783–90.

    CAS  CrossRef  PubMed  Google Scholar 

  42. Tester W, Caplan R, Heaney J, Venner P, Whittington R, Byhardt R, et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol. 1996;14(1):119–26. doi:10.1200/jco.1996.14.1.119.

    CAS  CrossRef  PubMed  Google Scholar 

  43. Kaufman D, Raghavan D, Carducci M, Levine EG, Murphy B, Aisner J, et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol. 2000;18(9):1921–7. doi:10.1200/jco.2000.18.9.1921.

    CAS  CrossRef  Google Scholar 

  44. Kaufman DS, Winter KA, Shipley WU, Heney NM, Wallace HJ 3rd, Toonkel LM, et al. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology. 2009;73(4):833–7. doi:10.1016/j.urology.2008.09.036.

    CrossRef  PubMed  Google Scholar 

  45. Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, Rodel CM, et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol. 2014;66(1):120–37. doi:10.1016/j.eururo.2014.02.038.

    CAS  CrossRef  PubMed  Google Scholar 

  46. Zehnder P, Studer UE, Skinner EC, Dorin RP, Cai J, Roth B, et al. Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. J Urol. 2011;186(4):1261–8. doi:10.1016/j.juro.2011.06.004.

    CrossRef  PubMed  Google Scholar 

  47. Rothwell RI, Ash DV, Jones WG. Radiation treatment planning for bladder cancer: a comparison of cystogram localisation with computed tomography. Clin Radiol. 1983;34(1):103–11.

    CAS  CrossRef  PubMed  Google Scholar 

  48. Muren LP, Smaaland R, Dahl O. Organ motion, set-up variation and treatment margins in radical radiotherapy of urinary bladder cancer. Radiother Oncol. 2003;69(3):291–304.

    CrossRef  Google Scholar 

  49. Cowan RA, McBain CA, Ryder WD, Wylie JP, Logue JP, Turner SL, et al. Radiotherapy for muscle-invasive carcinoma of the bladder: results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59(1):197–207. doi:10.1016/j.ijrobp.2003.10.018.

    CrossRef  PubMed  Google Scholar 

  50. Fokdal L, Hoyer M, von der Maase H. Treatment outcome and prognostic variables for local control and survival in patients receiving radical radiotherapy for urinary bladder cancer. Acta Oncol. 2004;43(8):749–57. doi:10.1080/02841860410018629.

    CrossRef  PubMed  Google Scholar 

  51. Davidson SE, Symonds RP, Snee MP, Upadhyay S, Habeshaw T, Robertson AG. Assessment of factors influencing the outcome of radiotherapy for bladder cancer. Br J Urol. 1990;66(3):288–93.

    CAS  CrossRef  PubMed  Google Scholar 

  52. Fokdal L, Hoyer M, von der Maase H. Radical radiotherapy for urinary bladder cancer: treatment outcomes. Expert Rev Anticancer Ther. 2006;6(2):269–79. doi:10.1586/14737140.6.2.269.

    CrossRef  PubMed  Google Scholar 

  53. Leissner J, Ghoneim MA, Abol-Enein H, Thuroff JW, Franzaring L, Fisch M, et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J Urol. 2004;171(1):139–44. doi:10.1097/01.ju.0000102302.26806.fb.

    CAS  CrossRef  PubMed  Google Scholar 

  54. Turner SL, Swindell R, Bowl N, Marrs J, Brookes B, Read G, et al. Bladder movement during radiation therapy for bladder cancer: implications for treatment planning. Int J Radiat Oncol Biol Phys. 1997;39(2):355–60.

    CAS  CrossRef  Google Scholar 

  55. Blank LE, Koedooder K, van Os R, van de Kar M, van der Veen JH, Koning CC. Results of bladder-conserving treatment, consisting of brachytherapy combined with limited surgery and external beam radiotherapy, for patients with solitary T1-T3 bladder tumors less than 5 cm in diameter. Int J Radiat Oncol Biol Phys. 2007;69(2):454–8. doi:10.1016/j.ijrobp.2007.03.014.

  56. van der Steen-Banasik E, Ploeg M, Witjes JA, van Rey FS, Idema JG, Heijbroek RP, et al. Brachytherapy versus cystectomy in solitary bladder cancer: a case control, multicentre, East-Netherlands study. Radiother Oncol. 2009;93(2):352–7. doi:10.1016/j.radonc.2009.04.020.

    CrossRef  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ozan Cem Guler M.D. .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Guler, O.C., Onal, C. (2017). Bladder Preservation Therapies in Bladder Cancer. In: Ozyigit, G., Selek, U. (eds) Principles and Practice of Urooncology. Springer, Cham. https://doi.org/10.1007/978-3-319-56114-1_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56114-1_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56113-4

  • Online ISBN: 978-3-319-56114-1

  • eBook Packages: MedicineMedicine (R0)